ClinicalTrials.gg
RecruitingNCT05491577CHARQUAMUpdated Oct 23, 2026

Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot

An observational study in Charcot Joint of Foot and Osteoarthropathy, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Oct 23, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Complications with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Complications · France.

Started
2023
with 2 others
Observational
4 of 11
2 open now
Registered
8th of 11
by date
Lead sponsor
3 of 11
Centre Hospitalier Universitaire de Nīmes

Among the 11 studies in Diabetes Complications with a site in France, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 8th registered.

Diabetes Complications

267 studies on the registry are indexed under Diabetes Complications; 54 are open to participants now.

Browse Diabetes Complications studies →

Open to participants now

3 of the 11 studies in Diabetes Complications with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 45 Diabetes Complications studies recruiting now, 27 (60%) set no upper age limit and 12 (27%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Complications with a site in France, or all of them as a file.
02

Study summary

Charcot foot, characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot, is a complication of diabetes that is still poorly understood by patients and caregivers. The clinical signs are non-specific and it is therefore largely underestimated due to a delay in diagnosis/lack of diagnosis.This study will be on a prospective multicenter cohort of patients with chronic Charcot's foot in France to evaluate the evolution of quality of life at 2 years, as well as predictive factors in order to better identify subjects with the worst outcome among this population.

Our hypothesis is that, in patients with chronic Charcot foot, the deterioration in quality of life over time is primarily related to loss of foot and ankle functionality, foot and ankle deformity and the presence of foot wounds/comorbidities/severe diabetic complications.

Read the detailed description

Diabetes mellitus is a chronic disease, representing a major public health problem. An estimated 537 million people have diabetes. Charcot foot, also known as neurogenic osteoarthropathy (NAO), is one of the complications of diabetes secondary to diabetic neuropathy. It is characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot. Charcot foot is a complication of diabetes that is still poorly understood by patients and caregivers, with non-specific clinical signs. It is therefore largely underestimated, since it is estimated that there is a delay in diagnosis or a lack of diagnosis in approximately 25% of cases.

The objective of our study is to conduct a prospective multicenter cohort of patients with chronic Charcot's foot in France in order to evaluate the evolution of the quality of life at 2 years, as well as its predictive factors. In this way, we will be better able to identify the subjects with the worst outcome among the chronic Charcot foot population.

Our hypothesis is that the deterioration in quality of life over time in patients with chronic Charcot foot is primarily related to loss of foot and ankle functionality, foot and ankle deformity, the presence of foot wounds and/or comorbidities or severe diabetic complications.

03

Conditions studied

  • Charcot Joint of Foot
  • Osteoarthropathy

Keywords

  • Diabetes complications
  • Diabetic foot
  • Osteoarthropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The source population corresponds to all diabetic patients (Type 1, 2 or secondary diabetes) hospitalized or consulting for chronic diabetic osteoarthropathy of the nerves, without wound managed in the participating centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with Type 1 or 2 diabetes or secondary diabetes
  • patient hospitalized or consulting for osteoarthropathy in its chronic stage, without wounds
  • patients affiliated to or beneficiaries of a health insurance scheme.
  • adult patients (≥18 years old).

Exclusion criteria

Exclusion Criteria:

  • patients with non-diabetic osteoarthropathy of the nerves.
  • patients with acute diabetic osteoarthropathy of the nerves.
  • patients with a foot ulcer
  • patients who have expressed opposition to participating in the study.
  • patients in an exclusion period determined by another study.
  • patients under court protection, guardianship or trusteeship.
  • patients for whom it is impossible to give informed information.
  • pregnant, parturient, or breastfeeding patients.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • OtherFilling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire

    The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.

06

What researchers measure

Primary outcomes

  1. Results of the SF36 questionnaire at inclusion

    The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.

    Time frame: Day 0

  2. Results of the FAAM-F questionnaire at inclusion

    The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.

    Time frame: Day 0

  3. Results of the SF36 questionnaire at Month 12

    The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.

    Time frame: Month 12

  4. Results of the FAAM-F questionnaire at Month 12

    The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.

    Time frame: Month 12

  5. Results of the SF36 questionnaire at Month 24

    The SF-36 questionnaire is a quality of life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.

    Time frame: Month 24

  6. Results of the FAAM-F questionnaire at Month 24

    The FAAM is a self-administered questionnaire that measures physical function of the foot and ankle. It is adapted and validated in the evaluation of diabetic foot disease. It consists of an assessment of activity of daily living and a sports assessment. The FAAM has been translated and validated in French. Score from 0 to 100.

    Time frame: Month 24

Secondary outcomes

  1. A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)

    In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.

    Time frame: Day 0

  2. A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)

    In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.

    Time frame: Month 12

  3. A. Evolution of X-ray measurements of bone and joint deformity of the foot. Lisfranc metatarsal misalignment (Méary's Line)

    In normal metatarsal alignment, the lateral border of the 1st metatarsal is aligned with lateral border of 1st (medial) cuneiform. The medial border of 2nd metatarsal is aligned with the medial border of 2nd (intermediate) cuneiform.The medial border of the 3rd (lateral) cuneiform should align with the medial border of the 3rd metatarsal. The lateral border of the 3rd (lateral) cuneiform should align with the lateral border of the 3rd metatarsal. The medial border of the 4th metatarsal is aligned with the medial border of the cuboid. The lateral margin of the 5th metatarsal can project lateral to cuboid by up to 3 mm on oblique. This alignment is known as the Méary Line and is assessed in front view.

    Time frame: Month 24

  4. A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.

    Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.

    Time frame: Day 0

  5. A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.

    Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.

    Time frame: Month 12

  6. A. Evolution of the radiologic measurements of bone and joint deformity of the foot: Méary's angle.

    Meary's angle (the angle between the line from the center of the talus body, intersecting the neck and head of the talus, and the line through the longitudinal axis of the 1st metatarsal) will be measured in profile view, in degrees. The normal value is about 0°.

    Time frame: Month 24

  7. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope

    The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.

    Time frame: Day 0

  8. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope

    The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.

    Time frame: Month 12

  9. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Calcaneal slope

    The calcaneal slope angle (line tangent to the inferior cortex of the calcaneus (angle between this line and a horizontal line) will be measured in degrees. Normal values are10-30° on the profile X-ray.

    Time frame: Month 24

  10. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle

    The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.

    Time frame: Day 0

  11. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle

    The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.

    Time frame: Month 12

  12. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Djian Annonier angle

    The Djian-Annonier angle will be measured (line between lower point of the talo-navicular joint and lower point of the medial sesamoid bone at the hallux). Line tangent to the inferior surface of the calcaneus. Normal value: 120-130° on profile X-ray.

    Time frame: Month 24

  13. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment

    The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..

    Time frame: Day 0

  14. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment

    The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..

    Time frame: Month 12

  15. A. Evolution of the radiologic measurements of bone and joint deformity of the foot. Rearfoot alignment

    The rearfoot alignment angle i.e. angle between the axis of the tibia and the line between the middle of the plantar support plane and the middle of talus will be measured in degrees..

    Time frame: Month 24

  16. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Retinopathy

    YES/NO

    Time frame: Month 24

  17. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Retinopathy

    YES/NO

    Time frame: Month 12

  18. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.

    YES/NO

    Time frame: Day 0

  19. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.

    YES/NO

    Time frame: Month 12

  20. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Peripheral vegetative neuropathy.

    YES/NO

    Time frame: Month 24

  21. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.

    YES/NO

    Time frame: Day 0

  22. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.

    YES/NO

    Time frame: Month 12

  23. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Nephropathy.

    YES/NO

    Time frame: Month 24

  24. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy

    YES/NO

    Time frame: Day 0

  25. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy

    YES/NO

    Time frame: Month 12

  26. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Lower extremity arteriopathy

    YES/NO

    Time frame: Month 24

  27. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement

    YES/NO

    Time frame: Day 0

  28. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement

    YES/NO

    Time frame: Month 12

  29. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Supra-aortic trunk involvement

    YES/NO

    Time frame: Month 24

  30. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease

    YES/NO

    Time frame: Day 0

  31. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease

    YES/NO

    Time frame: Month 12

  32. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Coronary artery disease

    YES/NO

    Time frame: Month 24

  33. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure

    YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)

    Time frame: Day 0

  34. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure

    YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)

    Time frame: Month 12

  35. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Heart failure

    YES/NO (measured according to a Left Ventricle Ejection Fraction of less than 50%)

    Time frame: Month 24

  36. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes

    YES/NO

    Time frame: Day 0

  37. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes

    YES/NO

    Time frame: Month 12

  38. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. History of strokes

    YES/NO

    Time frame: Month 24

  39. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension

    Pressure over 140/90mmHg : YES/NO

    Time frame: Day 0

  40. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension

    Pressure over 140/90mmHg : YES/NO

    Time frame: Month 12

  41. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Arterial hypertension

    Pressure over 140/90mmHg : YES/NO

    Time frame: Month 24

  42. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking

    Does the patient smoke : YES/NO

    Time frame: Day 0

  43. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking

    Does the patient smoke : YES/NO

    Time frame: Month 12

  44. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Smoking

    Does the patient smoke : YES/NO

    Time frame: Month 24

  45. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status

    Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score

    Time frame: Day 0

  46. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status

    Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score

    Time frame: Month 12

  47. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Alcohol status

    Does the patient drink more than 3 glasses of alcohol per day : YES/NO alcohol status Charlson score

    Time frame: Month 24

  48. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index

    The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.

    Time frame: Day 0

  49. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index

    The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.

    Time frame: Month 12

  50. B. Estimated prevalence of complications of diabetes and comorbidities at inclusion. Charlson Comorbidity Index

    The Charlson comorbidity index predicts the 1-year mortality for patient with a range of comorbid conditions, e.g. heart disease, AIDS, or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one. Scores are summed to provide a total score to predict mortality. Clinical conditions and associated scores are as follows: 1. each: Myocardial infarct, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, ulcer, chronic liver disease, diabetes. 2. each: Hemiplegia, moderate or severe kidney disease, diabetes with end organ damage, tumor, leukemia, lymphoma. 3. each: Moderate or severe liver disease. 6 each: Malignant tumor, metastasis, AIDS.

    Time frame: Month 24

  51. C. Medical and/or surgical treatment for Charcot foot.

    All medical and/or surgical treatment for Charcot foot will be recorded.

    Time frame: Day 0

  52. C. Medical and/or surgical treatment for Charcot foot.

    All medical and/or surgical treatment for Charcot foot will be recorded.

    Time frame: Month 12

  53. C. Medical and/or surgical treatment for Charcot foot.

    All medical and/or surgical treatment for Charcot foot will be recorded.

    Time frame: Month 24

  54. D. Incidence of hospitalization

    The number of hospitalizations (if any) will be noted.

    Time frame: Month 12

  55. D. Incidence of hospitalization

    The number of hospitalizations (if any) will be noted.

    Time frame: Month 24

  56. E. Presence of a wound/wounds

    YES/NO and number thereof.

    Time frame: Month 12

  57. E. Presence of a wound/wounds

    YES/NO and number thereof.

    Time frame: Month 24

  58. E. Presence of an infection

    YES/NO

    Time frame: Month 12

  59. E. Presence of an infection

    YES/NO

    Time frame: Month 24

  60. F. Presence of an amputation at inclusion

    YES/NO (or, if planned, time to amputation in days).

    Time frame: Day 0

  61. G. Estimated incidence of amputations

    YES/NO (or, if planned, time to amputation in days).

    Time frame: Month 12

  62. G. Presence of an amputation

    YES/NO (or, if planned, time to amputation in days).

    Time frame: Month 24

  63. H. Precarity of patients with chronic Charcot foot.

    The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.

    Time frame: Day 0

  64. H. Precarity of patients with chronic Charcot foot.

    The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.

    Time frame: Month 12

  65. H. Precarity of patients with chronic Charcot foot.

    The EPICES (Evaluation de la précarité et des inégalités de santé dans les Centres d'examens) score is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. The main interest of the EPICES score is to capture populations which, while not covered by traditional administrative indicators of precariousness present the same health risks. A threshold of 30 is considered as precariousness according to EPICES.

    Time frame: Month 24

  66. I. Depression according to the PHQ-2 self-questionnaire

    The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.

    Time frame: Day 0

  67. I. Depression according to the PHQ-2 self-questionnaire

    The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.

    Time frame: Month 24

  68. I. Depression according to the PHQ-2 self-questionnaire

    The purpose of the PHQ-2 is to screen for depression in a "first-step" approach. there are 2 questions referring to the patient's feelings over the previous 2 weeks ( 0 = Not at all and 3 = Nearly every day). A PHQ-2 score ranges from 0-6 and a score of 3 is the optimal cutoff point when using the PHQ-2 to screen for depression. If the score is 3 or greater, major depressive disorder is likely and the PHQ-9 questionnaire should then be used.

    Time frame: Month 12

  69. I. Depression according to the PHQ-9 self-questionnaire

    The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.

    Time frame: Day 0

  70. I. Depression according to the PHQ-9 self-questionnaire

    The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.

    Time frame: Month 12

  71. I. Depression according to the PHQ-9 self-questionnaire

    The PHQ-9 questionnaire is a set of 9 questions referring to the patients feelings over the previous 2 weeks with answers ranging from 0 = Not at all to 3 = Nearly every day. Interpreted as follows : 1-4 = minimum depression ; 5-9 = slight depression;10-14 = moderate depression;15-19 = moderately severe depression and 20-27 = severe depression.

    Time frame: Month 24

  72. J. Mortality rate

    Vital status (dead/alive)

    Time frame: Month 12

  73. J. Mortality rate

    Vital status (dead/alive)

    Time frame: Month 24

  74. K. Sanders Classification of the Charcot Foot

    The Sanders classification will be used to assess the degree of damage to the patient's foot as follows : Sanders I = Metatarsophalangeal involvement (forefoot) Sanders II= Tarsometatarsal joint involvement Sanders III= Tarsal joints involvement Sanders IV= Ankle involvement Sanders V= Posterior calcaneus involvement (tuberosity of the calcaneus, avulsion of the Achilles tendon) and all information will be recorded for the evaluation of the patient's quality of life.

    Time frame: Day 0

  75. K. Sanders Classification of the Charcot Foot

    The Sanders classification will be used to assess the degree of damage to the patient's foot as follows : Sanders I = Metatarsophalangeal involvement (forefoot) Sanders II= Tarsometatarsal joint involvement Sanders III= Tarsal joints involvement Sanders IV= Ankle involvement Sanders V= Posterior calcaneus involvement (tuberosity of the calcaneus, avulsion of the Achilles tendon) and all information will be recorded for the evaluation of the patient's quality of life.

    Time frame: Month 12

Other outcomes

  1. Sex of patients

    MALE/FEMALE

    Time frame: Day 0

  2. Age of patients

    In years

    Time frame: Day 0

  3. Patient's personal situation

    Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy

    Time frame: Day 0

  4. Patient's personal situation

    Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy

    Time frame: Month 12

  5. Patient's personal situation

    Lives alone/ Lives with family or has family nearby/Primary caregiver of another person/Lives in a bungalow/ Lives in a 2 or 3-storey house/ No fixed abode / Visits from a state-registered nurse/ Home help / Physiotherapy

    Time frame: Month 24

  6. Patient's level of education

    The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).

    Time frame: Day 0

  7. Patient's level of education

    The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).

    Time frame: Month 12

  8. Patient's level of education

    The patient's level of education will be recorded: No diploma (including: no schooling or schooling completed before the end of elementary school; schooling completed until the end of elementary school or completed before the end of junior high school; schooling until the end of junior high school or beyond) * Primary school certificate; * BEPC, brevet élémentaire, brevet des collèges, DNB ; * CAP, BEP or equivalent diploma; * Baccalaureate, vocational diploma including: general or technological baccalaureate, higher diploma, capacity in law, DAEU, ESEU; vocational baccalaureate, vocational, technician or teaching diploma, equivalent diploma; * BTS, DUT, DEUG, DEUST, health or social diploma of Bac+2 level, equivalent diploma; * Bachelor's degree, professional license, master's degree, equivalent diploma of bac+3 or bac+4 level; * Master's degree, DEA, DESS, diploma from an engineering school at Bac+5 level, health doctorate; * Research doctorate (not in health).

    Time frame: Month 24

  9. Patient's professional activity

    The patient's professional activity (if any) will be recorded

    Time frame: Day 0

  10. Patient's professional activity

    The patient's professional activity (if any) will be recorded

    Time frame: Month 12

  11. Patient's professional activity

    The patient's professional activity (if any) will be recorded

    Time frame: Month 24

  12. Nature of diabetes

    The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).

    Time frame: Day 0

  13. Nature of diabetes

    The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).

    Time frame: Month 12

  14. Nature of diabetes

    The nature of the patient's diabetes will be recorded (Type 1, Type 2, unknown, other).

    Time frame: Month 24

  15. Age of diabetes

    The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).

    Time frame: Day 0

  16. Age of diabetes

    The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).

    Time frame: Month 12

  17. Age of diabetes

    The age of the patient's diabetes will be recorded (More than 20 years/ 10 to 20 years/ 5 to 10 years/ less than 5 years/ unknown).

    Time frame: Month 24

  18. Presence of other complications: Retinopathy

    YES/NO

    Time frame: Day 0

  19. Presence of other complications: Retinopathy

    YES/NO

    Time frame: Month 12

  20. Presence of other complications: Retinopathy

    YES/NO

    Time frame: Month 24

  21. Presence of other complications: decreased visual acuity

    YES/NO

    Time frame: Day 0

  22. Presence of other complications: decreased visual acuity

    YES/NO

    Time frame: Month 12

  23. Presence of other complications: decreased visual acuity

    YES/NO

    Time frame: Month 24

  24. Presence of other complications: Nephropathy

    YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)

    Time frame: Day 0

  25. Presence of other complications: Nephropathy

    YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)

    Time frame: Month 12

  26. Presence of other complications: Nephropathy

    YES/NO and the nature thereof (Insipid nephropathy / Proteinuric nephropathy / Chronic kidney failure)

    Time frame: Month 24

  27. Presence of other complications: Abnormal glomerular filtration rate (GFR)

    GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²

    Time frame: Day 0

  28. Presence of other complications: Abnormal glomerular filtration rate (GFR)

    GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²

    Time frame: Month 12

  29. Presence of other complications: Abnormal glomerular filtration rate (GFR)

    GFR between 60 and 89ml/min/1.73 m² / GFR between 15 and 29ml/min/1.73 m² / GFR \< 15 ml/min/1.73 m²

    Time frame: Month 24

  30. Presence of other complications: dialysis

    YES/NO

    Time frame: Day 0

  31. Presence of other complications: dialysis

    YES/NO

    Time frame: Month 12

  32. Presence of other complications: dialysis

    YES/NO

    Time frame: Month 24

  33. Presence of other complications: peripheral neuropathy

    YES/NO and the nature thereof: monofilament (normal, pathological, not done)

    Time frame: Day 0

  34. Presence of other complications: peripheral neuropathy

    YES/NO and the nature thereof: monofilament (normal, pathological, not done)

    Time frame: Month 12

  35. Presence of other complications: peripheral neuropathy

    YES/NO and the nature thereof: monofilament (normal, pathological, not done)

    Time frame: Month 24

  36. Presence of other complications: vegetative neuropathy

    YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)

    Time frame: Day 0

  37. Presence of other complications: vegetative neuropathy

    YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)

    Time frame: Month 12

  38. Presence of other complications: vegetative neuropathy

    YES/NO and the nature thereof: (bladder, digestive, erectile dysfunction, orthostatic arterial hypotension)

    Time frame: Month 24

  39. Presence of other complications: coronaropathy

    YES/NO

    Time frame: Day 0

  40. Presence of other complications: coronaropathy

    YES/NO

    Time frame: Month 12

  41. Presence of other complications: coronaropathy

    YES/NO

    Time frame: Month 24

  42. Presence of other complications: heart failure

    YES/NO

    Time frame: Day 0

  43. Presence of other complications: heart failure

    YES/NO

    Time frame: Month 12

  44. Presence of other complications: heart failure

    YES/NO

    Time frame: Month 24

  45. Presence of other complications: arteriopathy of the lower limbs

    YES/NO and the nature thereof (revascularised or not/left or right side)

    Time frame: Day 0

  46. Presence of other complications: arteriopathy of the lower limbs

    YES/NO and the nature thereof (revascularised or not/left or right side)

    Time frame: Month 12

  47. Presence of other complications: arteriopathy of the lower limbs

    YES/NO and the nature thereof (revascularised or not/left or right side)

    Time frame: Month 24

  48. Presence of other complications: involvement of the supra-aortic trunk

    YES/NO

    Time frame: Day 0

  49. Presence of other complications: involvement of the supra-aortic trunk

    YES/NO

    Time frame: Month 12

  50. Presence of other complications: involvement of the supra-aortic trunk

    YES/NO

    Time frame: Month 24

  51. Presence of other complications: stroke

    YES/NO

    Time frame: Day 0

  52. Presence of other complications: stroke

    YES/NO

    Time frame: Month 12

  53. Presence of other complications: stroke

    YES/NO

    Time frame: Month 24

  54. Presence of other complications: sequellar hemiplegia

    YES/NO

    Time frame: Day 0

  55. Presence of other complications: sequellar hemiplegia

    YES/NO

    Time frame: Month 12

  56. Presence of other complications: sequellar hemiplegia

    YES/NO

    Time frame: Month 24

  57. Treatments: oral antidiabetics

    The nature of all oral antidiabetics will be recorded.

    Time frame: Day 0

  58. Treatments: oral antidiabetics

    The nature of all oral antidiabetics will be recorded.

    Time frame: Month 12

  59. Treatments: oral antidiabetics

    The nature of all oral antidiabetics will be recorded.

    Time frame: Month 24

  60. Treatments: injectable antidiabetics

    The nature of all injectable antidiabetics will be recorded.

    Time frame: Day 0

  61. Treatments: injectable antidiabetics

    The nature of all injectable antidiabetics will be recorded.

    Time frame: Month 12

  62. Treatments: injectable antidiabetics

    The nature of all injectable antidiabetics will be recorded.

    Time frame: Month 24

  63. Other treatments

    The nature of all other treatments will be recorded.

    Time frame: Day 0

  64. Other treatments

    The nature of all other treatments will be recorded.

    Time frame: Month 12

  65. Other treatments

    The nature of all other treatments will be recorded.

    Time frame: Month 24

  66. History of trophic disorders

    YES/NO and, if so, left/right, both feet.

    Time frame: Day 0

  67. History of trophic disorders

    YES/NO and, if so, left/right, both feet.

    Time frame: Month 12

  68. History of trophic disorders

    YES/NO and, if so, left/right, both feet.

    Time frame: Month 24

  69. Regular pedicure treatments

    The number and frequency of pedicure sessions per year will be recorded (if any).

    Time frame: Day 0

  70. Regular pedicure treatments

    The number and frequency of pedicure sessions per year will be recorded (if any).

    Time frame: Month 12

  71. Regular pedicure treatments

    YES/NO and, if so, number and frequency of pedicure sessions per year will be recorded (if any).

    Time frame: Month 24

  72. Weight

    Kilos

    Time frame: Day 0

  73. Weight

    Kilos

    Time frame: Month 12

  74. Weight

    Kilos

    Time frame: Month 24

  75. Height

    Centimeters

    Time frame: Day 0

  76. Height

    Centimeters

    Time frame: Month 12

  77. Height

    Centimeters

    Time frame: Month 24

  78. Charcot foot

    Left/right/both

    Time frame: Day 0

  79. Charcot foot

    Left/right/both

    Time frame: Month 12

  80. Charcot foot

    Left/right/both

    Time frame: Month 24

  81. Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy

    In years

    Time frame: Day 0

  82. Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy

    In years

    Time frame: Month 12

  83. Estimated age of lesions (deformities) caused by neurogenic osteoarthropathy

    In years

    Time frame: Month 24

  84. Neurogenic osteoarthropathy Sanders classification

    Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum

    Time frame: Day 0

  85. Neurogenic osteoarthropathy Sanders classification

    Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum

    Time frame: Month 12

  86. Neurogenic osteoarthropathy Sanders classification

    Sanders 1: interphalangeal and metatarsophalangeal joints Sanders 2: tarsometatarsal joints Sanders 3 : naviculocuneiform, talonavicular or calcaneocuboid joints Sanders 4 : ankle joint, subtalar joint Sanders 5: calcaneum

    Time frame: Month 24

  87. Current mode of shoeing/unfastening at home

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Day 0

  88. Current mode of shoeing/unfastening outdoors

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Day 0

  89. Current mode of shoeing/unfastening at home

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Month 12

  90. Current mode of shoeing/unfastening outdoors

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Month 12

  91. Current mode of shoeing/unfastening at home

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Month 24

  92. Current mode of shoeing/unfastening outdoors

    Barefoot and/or socks; serial sock; serial medical sock; normal shoe; normal medical shoe; foot orthosis; orthopedic low shaft shoe; orthopedic high shaft shoe; standard off-loading shoe; custom off-loading shoe ; standard removable boot; custom removable boot; non-removable boot; other...

    Time frame: Month 24

  93. Adherence to shoeing method

    At home/outdoors

    Time frame: Day 0

  94. Adherence to shoeing method

    At home/outdoors

    Time frame: Month 12

  95. Adherence to shoeing method

    At home/outdoors

    Time frame: Month 24

  96. Presence of another trophic foot disorder during the previous year

    YES/NO and date of onset of the ulcer (month and year)

    Time frame: Day 0

  97. Presence of another trophic foot disorder during the previous year

    YES/NO and date of onset of the ulcer (month and year)

    Time frame: Month 12

  98. Presence of another trophic foot disorder during the previous year

    YES/NO and date of onset of the ulcer (month and year)

    Time frame: Month 24

  99. Presence of a clinical infection

    YES/NO and, if so, the Infectious Diseases Society of America classification

    Time frame: Day 0

  100. Presence of a clinical infection

    YES/NO and, if so, the Infectious Diseases Society of America classification

    Time frame: Month 12

  101. Presence of a clinical infection

    YES/NO and, if so, the Infectious Diseases Society of America classification

    Time frame: Month 24

  102. Foot or leg surgery in the previous year

    YES/NO and, if so, left/right

    Time frame: Day 0

  103. Foot or leg surgery in the previous year

    YES/NO and, if so, left/right

    Time frame: Month 12

  104. Foot or leg surgery in the previous year

    YES/NO and, if so, left/right

    Time frame: Month 24

  105. Partial foot amputation

    YES/NO and, if so, left/right

    Time frame: Day 0

  106. Partial foot amputation

    YES/NO and, if so, left/right

    Time frame: Month 12

  107. Partial foot amputation

    YES/NO and, if so, left/right

    Time frame: Month 24

  108. Trans-tibial amputation

    YES/NO and, if so, left/right

    Time frame: Day 0

  109. Trans-tibial amputation

    YES/NO and, if so, left/right

    Time frame: Month 12

  110. Trans-tibial amputation

    YES/NO and, if so, left/right

    Time frame: Month 24

  111. Trans-femoral amputation

    YES/NO and, if so, left/right

    Time frame: Day 0

  112. Trans-femoral amputation

    YES/NO and, if so, left/right

    Time frame: Month 12

  113. Trans-femoral amputation

    YES/NO and, if so, left/right

    Time frame: Month 24

  114. Other type of surgery

    All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.

    Time frame: Day 0

  115. Other type of surgery

    All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.

    Time frame: Month 12

  116. Other type of surgery

    All other types of surgery : septic surgery / correction of morphostatic disorders of the forefoot / internal and/or external fixators / bone graft / correction of club foot will be recorded.

    Time frame: Month 24

  117. Hospitalization in the previous year

    YES/NO and, if so, the reason why

    Time frame: Day 0

  118. Hospitalization in the previous year

    YES/NO and, if so, the reason why

    Time frame: Month 12

  119. Hospitalization in the previous year

    YES/NO and, if so, the reason why

    Time frame: Month 24

  120. Onset and management of a foot wound (medical or surgical)

    YES/NO and dates

    Time frame: Day 0

  121. Onset and management of a foot wound (medical or surgical)

    YES/NO and dates

    Time frame: Month 12

  122. Onset and management of a foot wound (medical or surgical)

    YES/NO and dates

    Time frame: Month 24

  123. Management of a Charcot foot

    YES/NO

    Time frame: Day 0

  124. Management of a Charcot foot

    YES/NO

    Time frame: Month 12

  125. Management of a Charcot foot

    YES/NO

    Time frame: Month 24

  126. Onset of a controlateral Charcot foot

    YES/NO

    Time frame: Day 0

  127. Onset of a controlateral Charcot foot

    YES/NO

    Time frame: Month 12

  128. Onset of a controlateral Charcot foot

    YES/NO

    Time frame: Month 24

  129. Diabetic imbalance

    YES/NO

    Time frame: Day 0

  130. Diabetic imbalance

    YES/NO

    Time frame: Month 12

  131. Diabetic imbalance

    YES/NO

    Time frame: Month 24

  132. Other comorbidity or other reason for surgery

    YES/NO

    Time frame: Day 0

  133. Other comorbidity or other reason for surgery

    YES/NO

    Time frame: Month 12

  134. Other comorbidity or other reason for surgery

    YES/NO

    Time frame: Month 24

  135. Monitoring of glycemic control by HbA1c

    HbA1c will be measured as a percentage

    Time frame: Day 0

  136. Monitoring of glycemic control by HbA1c

    HbA1c will be measured as a percentage

    Time frame: Month 12

  137. Monitoring of glycemic control by HbA1c

    HbA1c will be measured as a percentage

    Time frame: Month 24

  138. Monitoring of glomerular Filtration Rate

    ml/mn

    Time frame: Day 0

  139. Monitoring of glomerular Filtration Rate

    ml/mn

    Time frame: Month 12

  140. Monitoring of glomerular Filtration Rate

    ml/mn

    Time frame: Month 24

  141. X-ray of Charcot foot under loading (profile view)

    Measurement of the Djian Annonier angle and the Meary-Tomeno line

    Time frame: Day 0

  142. X-ray of Charcot foot under loading (profile view)

    Measurement of the Djian Annonier angle and the Meary-Tomeno line

    Time frame: Month 12

  143. X-ray of Charcot foot under loading (profile view)

    Measurement of the Djian Annonier angle and the Meary-Tomeno line

    Time frame: Month 24

  144. Front view X-ray of the ankle(s) under loading

    With Meary cerclage (metal cerclage of the hindfoot)

    Time frame: Day 0

  145. Front view X-ray of the ankle(s) under loading

    With Meary cerclage (metal cerclage of the hindfoot)

    Time frame: Month 12

  146. Front view X-ray of the ankle(s) under loading

    With Meary cerclage (metal cerclage of the hindfoot)

    Time frame: Month 24

07

Study locations

8 of 17 sites recruiting
  • Centre Hospitalier de Boulogne-sur-Mer
    Boulogne-sur-Mer, Pas-de-Calais 62200, France
    Not yet recruiting
  • Groupement Hospitalier Est, Hôpital Cardiologique Service de Diabétologie 28 Av du Doyen Lépine
    Bron, 69500, France
    Not yet recruiting
    • Myriam MORET, Dr · Contact
  • CH Sud Francilien Service de Diabétologie 40 Avenue Serge Dassault
    Corbeil-Essonnes, 91100, France
    Not yet recruiting
    • Dured DARDARI, Dr. · Contact
  • CHU de Grenoble Service d'Endocrinologie Allée des Sablons Les écrins
    Grenoble, 38043, France
    Not yet recruiting
    • Marie Muller, Dr. · Contact
  • Hôpital Hôtel dieu Service d'Endocrinologie 26 rue d'Harfleur
    Le Creusot, 71200, France
    Not yet recruiting
    • Haleh MOHEBBI, Dr. · Contact
  • CHU Bicêtre Service d'Endocrinologie et Maladies de la reproduction 78 rue du Général Leclerc
    Le Kremlin-Bicêtre, 94275, France
    Recruiting
    • Muriel BOURGEON, Dr · Contact
  • CH de Lens Unité de Diabétologie-Endocrinologie- Nutrition-Obésité Centre Hospitalier Dr SCHAFFNER 99 rte de La Bassée,
    Lens, 62307, France
    Recruiting
    • Fabrice DEVEMY, Dr · Contact
  • CHRU de Lille Service d'Endocrinologie Diabétologie et Métabolisme, Hôpital Claude Huriez, Rue Polonovski
    Lille, 59037, France
    Not yet recruiting
    • Florence BAUDOUX, Dr. · Contact
  • CHU de la CONCEPTION Service de Nutrition, Diabétologie, Obésité médicale, chirurgicale 47 Bd Baille
    Marseille, 13005, France
    Not yet recruiting
    • Rachel GRANGEOT-PATTE, Dr. · Contact
  • CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud
    Montpellier, 34295, France
    Recruiting
    • Ariane SULTAN, Pr · Contact
  • GH Pitié Salpétrière Unité de podologie Service de Diabétologie 47-83 Bd de l'Hôpital
    Paris, 750013, France
    Recruiting
    • Georges HA VAN, Dr. · Contact
  • GH Paris Saint Joseph Service de Diabétologie et Endocrinologie 185 rue Raymond Losserand
    Paris, 75014, France
    Recruiting
    • Olivier DUPUY, Dr. · Contact
    • Camille BAUDRY, Dr. · Sub investigator
    • Lucile JOLIE, Dr. · Sub investigator
    • Florence BOUILLOUD-CHATILLON, Dr. · Principal investigator
  • Hôpital Cochin Service de diabétologie 123 Bd de Port Royal
    Paris, 75014, France
    Not yet recruiting
    • Jocelyne MBEMBA, Dr · Contact
  • CHU de Lyon Sud Service d'Endocrinologie-Diabète-Nutrition CH Lyon Sud Pavillon médical, Bat 1B 165 chemin du Grand Revoyet
    Pierre-Bénite, 69495, France
    Recruiting
    • Julien VOUILLARMET, Dr. · Contact
  • CHU Reims Service d'Endocrinologie, diabète-nutrition Rue du Général Koenig
    Reims, 51092, France
    Recruiting
    • Maud FRANCOIS, Dr. · Contact
  • Hôpitaux Universitaires de Strasbourg Service d'Endocrinologie et Diabétologie 1, place de l'hôpital,
    Strasbourg, 61091, France
    Not yet recruiting
    • Laurence KESSLER, Dr. · Contact
  • Hôpital DRON Service de diabétologie 135 rue du Président Coty
    Tourcoing, 52208, France
    Recruiting
    • Marie CAZAUBIEL, Dr. · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jul 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2022
First posted
Aug 8, 2022
StartActual
Jan 23, 2023
Primary completionEst.
Jul 22, 2027
CompletionEst.
Jan 22, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud · Montpellier, France
Show 1 removed
  • CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud · Montpellier Cedex, France
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 1 site removed
    Show site
    • CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud · Montpellier, France
    Show 1 removed
    • CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud · Montpellier Cedex, France
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05491577
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Jan 23, 2023
Primary completion
Jul 22, 2027 (estimated)
Completion
Jan 22, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Sophie Schuldiner, Dr.
Contact
sophie.schuldiner@chu-nimes.fr
+33 4.66.68.33.21
Anissa MEGZARI
Contact
drc@chu-nimes.fr
+33 4.66.68.42.36
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion